Trial Profile
Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Carcinoid tumour; Malignant carcinoid syndrome
- Focus Registrational; Therapeutic Use
- 01 Jul 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Jan 2013 Planned initiation date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 09 Jul 2012 Planned End Date changed from 1 Sep 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov.